BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Clinical Outcome
27 results:

  • 1. Withaferin A mediated changes of miRNA expression in breast cancer-derived mammospheres.
    Prajapati KS; Shuaib M; Gupta S; Kumar S
    Mol Carcinog; 2022 Sep; 61(9):876-889. PubMed ID: 35770722
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Phase II Study of Taselisib in
    Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
    Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Correlation Between Onco-suppressors pten and NM23 and clinical outcome in Patients With T1 breast cancer.
    Izzo L; Messineo D; DI Cello P; Nicolanti V; Sterpetti A; Izzo S; Izzo P
    In Vivo; 2021; 35(1):169-174. PubMed ID: 33402463
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
    Parks RM; Albanghali MA; Syed BM; Green AR; Ellis IO; Cheung KL
    Breast Cancer Res Treat; 2021 Feb; 185(3):647-655. PubMed ID: 33226492
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Molecular stratification within triple-negative breast cancer subtypes.
    Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
    Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced breast cancer Treated with Lapatinib and Other Anti-HER2 Therapy.
    Kim SB; Do IG; Tsang J; Kim TY; Yap YS; Cornelio G; Gong G; Paik S; Lee S; Ng TY; Park S; Oh HS; Chiu J; Sohn J; Lee M; Choi YJ; Lee EM; Park KH; Nathaniel C; Ro J
    Cancer Res Treat; 2019 Oct; 51(4):1527-1539. PubMed ID: 31163957
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A subgroup of microRNAs defines pten-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
    Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung cancer.
    Sun L; Yuan H; Burnett J; Gasparyan M; Zhang Y; Zhang F; Yang Z; Ran Y; Sun D
    Int J Med Sci; 2019; 16(1):68-74. PubMed ID: 30662330
    [No Abstract]    [Full Text] [Related]  

  • 10. The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/pten signaling: Implicating TIGAR in somatic resistance to endocrine therapy.
    Fiorillo M; Sanchez-Alvarez R; Sotgia F; Lisanti MP
    Aging (Albany NY); 2018 Dec; 10(12):4000-4023. PubMed ID: 30573703
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
    Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL
    Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Mechanisms of Acquired Resistance to Trastuzumab Emtansine in breast cancer Cells.
    Li G; Guo J; Shen BQ; Yadav DB; Sliwkowski MX; Crocker LM; Lacap JA; Phillips GDL
    Mol Cancer Ther; 2018 Jul; 17(7):1441-1453. PubMed ID: 29695635
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. FoxO3a Mediates the Inhibitory Effects of the Antiepileptic Drug Lamotrigine on breast cancer Growth.
    Pellegrino M; Rizza P; Nigro A; Ceraldi R; Ricci E; Perrotta I; Aquila S; Lanzino M; Andò S; Morelli C; Sisci D
    Mol Cancer Res; 2018 Jun; 16(6):923-934. PubMed ID: 29523760
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.
    Okabe M; Toh U; Iwakuma N; Saku S; Akashi M; Kimitsuki Y; Seki N; Kawahara A; Ogo E; Itoh K; Akagi Y
    Cancer Sci; 2017 Jan; 108(1):81-90. PubMed ID: 27801993
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes.
    Liu R; Zhang W; Liu ZQ; Zhou HH
    Oncotarget; 2016 Apr; 7(16):21686-98. PubMed ID: 26934123
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing breast cancer.
    Menyhárt O; Santarpia L; Győrffy B
    Curr Cancer Drug Targets; 2015; 15(8):665-83. PubMed ID: 26452383
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. pten Loss Is Associated with Worse outcome in HER2-Amplified breast cancer Patients but Is Not Associated with Trastuzumab Resistance.
    Stern HM; Gardner H; Burzykowski T; Elatre W; O'Brien C; Lackner MR; Pestano GA; Santiago A; Villalobos I; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Nuciforo P; Bee V; Mackey J; Slamon DJ; Press MF
    Clin Cancer Res; 2015 May; 21(9):2065-74. PubMed ID: 25649019
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
    Baselga J; Cortés J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM
    J Clin Oncol; 2014 Nov; 32(33):3753-61. PubMed ID: 25332247
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.
    Cuorvo LV; Verderio P; Ciniselli CM; Girlando S; Decarli N; Leonardi E; Ferro A; Caldara A; Triolo R; Eccher C; Cantaloni C; Mauri F; Seckl M; Volante M; Buttitta F; Marchetti A; Silvia Q; Galligioni E; Palma PD; Barbareschi M
    Virchows Arch; 2014 Jan; 464(1):85-93. PubMed ID: 24233241
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors.
    Klajic J; Fleischer T; Dejeux E; Edvardsen H; Warnberg F; Bukholm I; Lønning PE; Solvang H; Børresen-Dale AL; Tost J; Kristensen VN
    BMC Cancer; 2013 Oct; 13():456. PubMed ID: 24093668
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.